Lopez L M, Mehta J L
Drug Intell Clin Pharm. 1985 Dec;19(12):928-32. doi: 10.1177/106002808501901214.
This study describes sustained efficacy and safety of lofexidine in hypertensive patients. Twenty-one male patients (mean age 55 +/- 9 yr) who had previously completed a short-term trial of lofexidine entered this open-label trial. The daily dose of lofexidine was titrated over three months to a maximum of 1.6 mg or an erect diastolic blood pressure less than 90 mm Hg. Hydrochlorothiazide was added when necessary. Thereafter, each patient was evaluated for blood pressure (BP) response, compliance, side effects, hepatic, renal, or hematological abnormalities every three months for two years. Sustained BP reduction with lofexidine was achieved but not without concomitant diuretic therapy. There were no clinically important changes in heart rate or hepatic, renal, or hematological profiles. Side effects were frequent but severe enough to warrant discontinuation in only four patients. The side-effect profile was similar to that of clonidine. We recommend concurrent diuretic use to maximize effectiveness of lofexidine.
本研究描述了洛非西定在高血压患者中的持续疗效和安全性。21名男性患者（平均年龄55±9岁）先前完成了洛非西定的短期试验，进入了这项开放标签试验。洛非西定的每日剂量在三个月内滴定至最大1.6毫克或直立舒张压低于90毫米汞柱。必要时添加氢氯噻嗪。此后，每三个月对每位患者进行一次血压（BP）反应、依从性、副作用、肝脏、肾脏或血液学异常评估，持续两年。使用洛非西定可实现血压持续降低，但离不开利尿剂联合治疗。心率或肝脏、肾脏或血液学指标无临床重要变化。副作用很常见，但严重到足以导致仅4名患者停药。副作用情况与可乐定相似。我们建议同时使用利尿剂以最大化洛非西定的疗效。
